Oncología médica
Especialidad
Universitat Autònoma de Barcelona
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Universitat Autònoma de Barcelona (18)
2024
-
The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
Current Oncology, Vol. 31, Núm. 9, pp. 5652-5661
2023
-
Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section
Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 796-802
-
Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes
The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106
-
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513
-
Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after
Quality of Life Research, Vol. 32, Núm. 4, pp. 989-1003
2021
-
Factors that Influence Treatment Delay for Patients with Breast Cancer
Annals of Surgical Oncology, Vol. 28, Núm. 7, pp. 3714-3721
2019
-
Cohort profile: Design and methods of the PREDIMED-Plus randomized trial
International Journal of Epidemiology, Vol. 48, Núm. 2, pp. 387-388o
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
-
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis
BMC Cancer, Vol. 15, Núm. 1
-
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies
Oncotarget, Vol. 6, Núm. 42, pp. 44254-44273
2013
2012
-
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
BMC Medical Genomics, Vol. 5
2010
-
Current perspectives of treatment of ductal carcinoma in situ
Cancer Treatment Reviews, Vol. 36, Núm. 7, pp. 507-517
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
2009
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967
1995
-
Anti-islet cell and anti-insulin antibody production by CD5+ and CD5- B lymphocytes in IDDM
Diabetologia: Clinical and Experimental Diabetes and Metabolism, Vol. 38, Núm. 1, pp. 62-72
1991
-
A phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer
Cancer, Vol. 68, Núm. 1, pp. 40-43
1989
-
Anticipatory nausea and vomiting: Prevalence and predictors in chemotherapy patients
Oncology (Switzerland), Vol. 46, Núm. 1, pp. 26-30